TrkB Receptor Overview and Therapeutic Modulation
The TrkB receptor (tropomyosin receptor kinase B) is a neurotrophin tyrosine kinase receptor encoded by the NTRK2 gene that can be therapeutically modulated through selective TRK inhibitors for NTRK fusion-positive cancers, or through TrkB agonists for neurological and psychiatric conditions.
Receptor Structure and Function
TrkB is a transmembrane receptor protein whose primary ligand is brain-derived neurotrophic factor (BDNF). In normal physiology, TrkB regulates:
- Neuronal development and survival during embryonic growth
- Mood regulation in postnatal life 1
- Synaptic plasticity and neuroplasticity in the adult brain 2
Upon ligand binding, TrkB receptors dimerize and become catalytically active through tyrosine phosphorylation, triggering downstream signaling through PI3K, phospholipase C-γ, and ERK1/2 MAP kinase pathways 1.
Pathological Activation in Cancer
NTRK2 Gene Fusions
Chromosomal translocations involving NTRK2 result in constitutive, ligand-independent activation of TrkB. The 5' region of a partner gene fuses with the 3' region of NTRK2, creating a fusion protein with the kinase domain that remains constantly active 1.
TrkB fusions occur in:
- Infantile fibrosarcoma and cellular congenital mesoblastic nephroma (high frequency)
- Undifferentiated sarcomas, gliomas, papillary thyroid cancers
- Spitzoid neoplasms, inflammatory myofibroblastic tumors
- Acute leukemias (lower frequencies) 1
Therapeutic Modulation Strategies
For NTRK Fusion-Positive Cancers
Selective TRK inhibitors are the standard approach for tumors harboring NTRK fusions, with larotrectinib demonstrating a 75% response rate across children and adults 1.
FDA-approved pan-TRK inhibitors include:
- Larotrectinib (first tumour-agnostic approval in 2018) - targets TRKA, TRKB, and TRKC 3
- Entrectinib (approved 2019) - targets TRKA, TRKB, TRKC, plus ROS1 and ALK 3
These agents work by blocking the constitutively active kinase domain, preventing downstream oncogenic signaling through PI3K and MAP kinase pathways 1.
For Neurological and Psychiatric Conditions
TrkB agonists represent an emerging therapeutic approach for conditions involving reduced BDNF-TrkB signaling:
Small Molecule Agonists
- LM22B-10 (C10): A blood-brain barrier-permeant TrkB/TrkC co-activator that increased neuronal progenitor cell proliferation and reduced cell death following traumatic brain injury in preclinical models 4
- 7,8-dihydroxyflavone (7,8-DHF): A TrkB agonist studied in inflammation-related depression models 5
Important caveat: LM22B-10 showed bimodal effects - promoting anxiety and diminishing spatial memory in uninjured animals while improving these behaviors after injury, suggesting excess neurotrophic activity may be detrimental in healthy tissue 4.
Agonistic Antibodies
Two categories of TrkB-agonistic antibodies have been developed 6:
- Orthosteric antibodies (e.g., AB2): Bind at the BDNF binding site
- Allosteric antibodies (e.g., AB20): Bind to the TrkB-d5 domain at a site distinct from BDNF
Both antibody types stimulated transcriptional changes overlapping with BDNF-driven modulation and activated downstream AKT and CREB phosphorylation. The allosteric and orthosteric antibodies can act synergistically at higher concentrations 6.
Antidepressant-Mediated Activation
Fluoxetine and other antidepressants act as allosteric potentiators of BDNF signaling through direct binding to the TrkB transmembrane domain 7. This mechanism explains why various antidepressant classes (typical, rapid-acting, and psychedelic compounds) share TrkB as a common target 2.
Clinical Screening Recommendations
For cancer patients, screening for NTRK fusions should follow this algorithm 1:
- High-prevalence tumors (infantile fibrosarcoma, cellular CMN, secretory breast cancer, MASC): Use immunohistochemistry or fluorescence in situ hybridization
- Low-prevalence tumors: Use next-generation sequencing to identify both NTRK fusions and other targetable oncogenic drivers
Key Limitations and Considerations
- TrkB agonists for neurological conditions remain largely experimental, with most evidence from preclinical models 4, 8
- Neuroprotective effects appear to depend on baseline injury status - beneficial after injury but potentially harmful in healthy tissue 4
- TrkB antagonists (e.g., ANA-12) may have therapeutic value in specific contexts like inflammation-induced depression 5
- The p75 neurotrophin receptor can bind BDNF and elicit unwanted side effects, making selective TrkB agonists preferable to exogenous BDNF administration 8